Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (2948)	8/13/2005 11:01:44 AM
From: former_pgs	Read Replies (1) \| Respond to of 12215

OT: Yeah, mass spec would definitely do it. If it was me in the lab, I wouldn't hinge my project on being able to generate a monoclonal against a 10-20 amino acid fragment that doesn't recognize the parent protein. Others here may look at that as a fun challenge, however... ;-) I'd say that CIPH's claims regarding the superiority of the mass spec method over an ELISA method are valid in this case. Despite being slower than ELISA on a per sample basis, mass spec isn't all that slow, and it will give you absolute values whereas an ELISA really won't. To digress... for a 151 amino acid serum protein, its cleaved fragment can be easily resolved by SDS-PAGE. You would not need any subsequent Western blotting since serum samples are generally "cleaner" than tissue samples, which was my first assumption of the protein source. You could easily run 100+ samples in 3 hours and get really nice, quantitative data at great sensitivity using fluorescent dyes. Of course as you said, selling gels is not as lucrative or sexy as selling a mass spec and accompanying consumables.